- Home
- NBIX
as 08-01-2025 4:00pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 13.2B | IPO Year: | 1996 |
| Target Price: | $165.59 | AVG Volume (30 days): | 935.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.39 | EPS Growth: | 2.97 |
| 52 Week Low/High: | $84.23 - $157.98 | Next Earning Date: | 07-30-2025 |
| Revenue: | $2,509,900,000 | Revenue Growth: | 18.42% |
| Revenue Growth (this year): | 16.12% | Revenue Growth (next year): | 15.06% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | NBIX | Director | May 27 '25 | Sell | $120.38 | 9,613 | $1,157,211.02 | 514,596 | |
| RASTETTER WILLIAM H | NBIX | Director | May 5 '25 | Sell | $110.20 | 30,000 | $3,305,952.00 | 37,491 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
High Growth Tech Stocks In US To Watch July 2025
Zacks
10 days ago
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
MT Newswires
12 days ago
Truist Securities Initiates Coverage on Neurocrine Biosciences With Buy Rating, $163 Price Target
PR Newswire
a month ago
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Argus Research
a month ago
NBIX: Raising target price to $135.00
Zacks
a month ago
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Simply Wall St.
a month ago
Exploring 3 High Growth Tech Stocks In The US Market
PR Newswire
a month ago
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.